The estimated Net Worth of Pharmaceuticals (Europe) Lt... is at least 245 百万$ dollars as of 26 December 2018. Pharmaceuticals Lt owns over 40,198 units of CRISPR Therapeutics AG stock worth over 244,509,914$ and over the last 6 years Pharmaceuticals sold CRSP stock worth over 0$.
Sign up
Pharmaceuticals Lt CRSP stock SEC Form 4 insiders trading
Pharmaceuticals has made over 2 trades of the CRISPR Therapeutics AG stock since 2018, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals bought 40,198 units of CRSP stock worth 1,002,136$ on 26 December 2018.
The largest trade Pharmaceuticals's ever made was buying 90,742 units of CRISPR Therapeutics AG stock on 21 December 2018 worth over 2,185,067$. On average, Pharmaceuticals trades about 65,470 units every 3 days since 2018. As of 26 December 2018 Pharmaceuticals still owns at least 5,380,940 units of CRISPR Therapeutics AG stock.
You can see the complete history of Pharmaceuticals Lt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharmaceuticals Lt's mailing address?
Pharmaceuticals's mailing address filed with the SEC is 9TH, 2 Kingdom St, London W2 6BD, UK.
Insiders trading at CRISPR Therapeutics AG
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over 284,003,967$ worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth 53,410,590$ . The most active insiders traders include Plc Gsk、Ali Behbahani、Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of 2,405,548$. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth 318,080$.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
What does CRISPR Therapeutics AG's logo look like?
Complete history of Pharmaceuticals Lt stock trades at CRISPR Therapeutics AG
CRISPR Therapeutics AG executives and stock owners
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include:
-
Samarth Kulkarni,
Chief Executive Officer, Director -
Lawrence Klein,
Chief Operating Officer, Chief Business Officer -
Tony Ho,
Executive Vice President - Research and Development -
James Kasinger,
General Counsel, Secretary -
Michael Tomsicek,
Chief Financial Officer -
Dr. Samarth Kulkarni,
CEO & Director -
Dr. Lawrence Otto Klein Ph.D.,
Chief Operating Officer -
James R. Kasinger,
Gen. Counsel & Sec. -
Rodger Novak,
Chairman of the Board, President, Co-Founder -
Dr. Rodger Novak M.D.,
Founder, Chairman & Pres -
Susan Kim,
IR Contact Officer -
Katherine High,
Independent Director -
John Greene,
Independent Director -
Simeon George,
Independent Director -
Bradley Bolzon,
Independent Director -
Ali Behbahani,
Independent Director -
Dr. Daniel G. Anderson Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Matthew Porteus M.D., Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Chad Cowan Ph.D.,
Scientific Founder -
Dr. Craig C. Mello Ph.D.,
Scientific Founder & Advisory Board Member -
Dr. Emmanuelle Marie Charpentier,
Co-Founder & Scientific Advisory Board Member -
Shaun Foy,
Founder -
Aktiengesellschaft Bayer Gl...,
-
Tyler Dylan Hyde,
Chief Legal Officer -
Pablo J Cagnoni,
Director -
Venture Capital Iv, L.P.Ver...,
-
Harbor Master Investors (Ca...,
10% owner -
Kurt Von Emster,
Director -
Sven Ante Lundberg,
Chief Scientific Officer -
Corp /De/ Celgene,
10% owner -
Kala Subramanian,
See Remarks -
Thomas Woiwode,
Director -
N Anthony Coles,
Director -
Plc Gsk,
10% owner -
Pharmaceuticals (Europe) Lt...,
-
Venture Capital Iv, L.P.Ver...,
-
Julianne Bruno,
Chief Operating Officer -
Brendan Smith,
Chief Financial Officer -
Venture Capital Iv, L.P.Ver...,
-
Venture Capital V, L.P.Vers...,
-
Naimish Patel,
Chief Medical Officer -
Harold Edward Fleming,
-
Maria Fardis,
-
Sandesh Mahatme,
-
Douglas A Treco,
-
Christian Rommel,
-
Phuong Khanh Morrow,
Chief Medical Officer -
Raju Prasad,
Chief Financial Officer